KUALA LUMPUR, Malaysia, July 6, 2026 — Cypress Pharmaceutical Group (“Cypress”) marked a significant milestone with its first-ever exhibition participation at the 37th Annual Scientific Congress of the Malaysian Oncological Society (ASCOMOS 2026) and the 59th Malaysia-Singapore Congress of Medicine, held from 3–5 July 2026 at the Kuala Lumpur Convention Centre.
ASCOMOS is one of the region’s leading oncology congresses, bringing together oncologists, researchers, healthcare professionals, and industry leaders to discuss the latest developments in cancer treatment, supportive care, and precision medicine. The 2026 congress provided an important platform for scientific exchange, collaboration, and innovation in advancing cancer care.
At the exhibition, Cypress showcased the strengths of its specialty healthcare businesses, Juniper Biologics and Cedar Pharmaceuticals, highlighting solutions that support the evolving needs of oncology care.
Juniper Biologics featured AKYNZEO®, an innovative fixed-dose combination antiemetic designed to help prevent chemotherapy-induced nausea and vomiting (CINV), supporting patients throughout their cancer treatment journey.
Cedar Pharmaceuticals showcased 1Cell.AI, an AI-powered precision oncology platform that leverages genomic insights to support personalized cancer care and clinical decision-making.
Throughout the three-day congress, the Cypress team engaged with healthcare professionals from across the region, exchanging insights on emerging treatment paradigms, supportive care strategies, precision oncology, and the future of cancer management. The event also provided valuable opportunities to strengthen partnerships and explore new collaborations aimed at improving patient outcomes.
The strong engagement and meaningful discussions with healthcare professionals throughout the congress reinforce our commitment to bringing innovative healthcare solutions to patients across Asia and beyond. We look forward to building on these connections and advancing our mission through collaboration, innovation, and scientific excellence.
The successful debut at ASCOMOS reflects Cypress Pharmaceutical Group’s commitment to advancing healthcare through innovation and strategic partnerships. Through its specialty businesses, Juniper Biologics and Cedar Pharmaceuticals, the Group continues to focus on delivering solutions that address unmet medical needs and support better outcomes for patients across the region.
As Cypress Pharmaceutical Group continues its growth journey, the company remains dedicated to bridging innovation and patient care, while fostering collaborations that contribute to the advancement of healthcare and precision medicine.